4D Molecular Therapeutics Inc
FDMT10.500USD
-0.420-3.85%
終値 11/07, 16:00（ET）15分遅れの株価
490.35M時価総額
損失額直近12ヶ月PER
詳細情報 4D Molecular Therapeutics Inc 企業名
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
4D Molecular Therapeutics Incの企業情報
企業コードFDMT
会社名4D Molecular Therapeutics Inc
上場日Dec 11, 2020
最高経営責任者「CEO」Dr. David Kirn, M.D.
従業員数227
証券種類Ordinary Share
決算期末Dec 11
本社所在地5858 Horton Street #455
都市EMERYVILLE
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号94608
電話番号15105052680
ウェブサイトhttps://4dmoleculartherapeutics.com/
企業コードFDMT
上場日Dec 11, 2020
最高経営責任者「CEO」Dr. David Kirn, M.D.
4D Molecular Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.66M
-0.02%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Mr. Ashoo Gupta
Mr. Ashoo Gupta
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
45.66K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Dhaval Desai, Pharm.D.
Dr. Dhaval Desai, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Charles P. Theuer, M.D., Ph.D.
Dr. Charles P. Theuer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Nancy Miller-Rich
Ms. Nancy Miller-Rich
Independent Director
Independent Director
--
--
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Simms
Mr. Christopher (Chris) Simms
Chief Commercial Officer
Chief Commercial Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.66M
-0.02%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Mr. Ashoo Gupta
Mr. Ashoo Gupta
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
45.66K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Dhaval Desai, Pharm.D.
Dr. Dhaval Desai, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
収益内訳
通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
データなし
地域別USD
会社名
収益
比率
United States
15.00K
0.00%
Netherlands
0.00
0.00%
事業別
地域別
データなし
株主
更新時刻: Sat, Nov 8
更新時刻: Sat, Nov 8
株主統計
種類
株主統計
株主統計
比率
BVF Partners L.P.
9.91%
RA Capital Management, LP
9.77%
Goldman Sachs & Company, Inc.
8.01%
Novo Holdings A/S
6.80%
BlackRock Institutional Trust Company, N.A.
6.67%
他の
58.84%
株主統計
株主統計
比率
BVF Partners L.P.
9.91%
RA Capital Management, LP
9.77%
Goldman Sachs & Company, Inc.
8.01%
Novo Holdings A/S
6.80%
BlackRock Institutional Trust Company, N.A.
6.67%
他の
58.84%
種類
株主統計
比率
Investment Advisor
19.79%
Investment Advisor/Hedge Fund
19.57%
Hedge Fund
17.68%
Venture Capital
17.25%
Research Firm
14.76%
Individual Investor
3.95%
Pension Fund
0.15%
Sovereign Wealth Fund
0.12%
Bank and Trust
0.11%
他の
6.63%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
353
39.94M
73.19%
-18.33M
2025Q2
351
46.37M
100.09%
-13.01M
2025Q1
358
46.38M
99.71%
-13.16M
2024Q4
357
49.60M
107.13%
-13.93M
2024Q3
350
60.77M
117.85%
-4.39M
2024Q2
340
60.30M
117.01%
-2.54M
2024Q1
324
59.47M
116.84%
+10.27M
2023Q4
284
45.54M
106.82%
-1.53M
2023Q3
275
45.63M
108.12%
-4.94M
2023Q2
263
44.82M
109.79%
-393.70K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
BVF Partners L.P.
4.63M
9.91%
+68.00K
+1.49%
Jun 30, 2025
RA Capital Management, LP
4.56M
9.77%
--
--
Jun 30, 2025
Goldman Sachs & Company, Inc.
3.74M
8.01%
-7.99K
-0.21%
Jun 30, 2025
Novo Holdings A/S
2.00M
4.28%
+50.00K
+2.56%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.12M
6.67%
-415.30K
-11.76%
Jun 30, 2025
The Vanguard Group, Inc.
2.74M
5.86%
-20.82K
-0.75%
Jun 30, 2025
Janus Henderson Investors
1.75M
3.76%
-137.53K
-7.27%
Jun 30, 2025
Kirn (David)
1.66M
3.55%
-360.00
-0.02%
Apr 24, 2025
Federated MDTA LLC
1.65M
3.54%
+411.45K
+33.10%
Jun 30, 2025
Millennium Management LLC
1.48M
3.18%
-150.26K
-9.20%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Thu, Nov 6
更新時刻: Thu, Nov 6
銘柄名
比率
Federated Hermes MDT Small Cap Core ETF
0.59%
iShares Micro-Cap ETF
0.07%
Harbor Human Capital Factor US Small Cap ETF
0.07%
iShares Health Innovation Active ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
詳細を見る
Federated Hermes MDT Small Cap Core ETF
比率0.59%
iShares Micro-Cap ETF
比率0.07%
Harbor Human Capital Factor US Small Cap ETF
比率0.07%
iShares Health Innovation Active ETF
比率0.05%
ProShares Ultra Nasdaq Biotechnology
比率0.04%
Invesco Nasdaq Biotechnology ETF
比率0.04%
iShares Biotechnology ETF
比率0.04%
Invesco RAFI US 1500 Small-Mid ETF
比率0.03%
Avantis US Small Cap Equity ETF
比率0.03%
iShares Russell 2000 Value ETF
比率0.02%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
